Preclinical Evaluation of 68 Ga/ 177 Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.124.268689 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Rang Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Lutetium, Serine Endopeptidases, Gelatinases. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 28 Literaturangaben.
Abstract (Originalsprache)
Fibroblast activation protein (FAP) has been considered a promising target for tumor imaging and therapy. This study designed a novel peptide, FAP-HXN, specifically targeting FAP and exhibiting significant potential as a radionuclide-labeled theranostic agent. Preclinical studies were conducted to evaluate the potency, selectivity, and efficacy of FAP-HXN.
Methods
FAP-HXN was synthesized and characterized for selectivity and specificity toward FAP. Cellular uptake of the radiolabeled FAP-HXN in human embryonic kidney (HEK)-293-FAP cells with high expressions of FAP was evaluated. The diagnostic and therapeutic potential of 68Ga- and 177Lu-labeled radioligands was evaluated in HEK-293-FAP tumor-bearing mice compared with the FAP-targeting peptide FAP-2286.
Results
FAP-HXN demonstrated high binding ability to human and mouse sources of FAP. Moreover, the in vivo studies confirmed the high affinity and specificity of radiolabeled FAP-HXN. Small-animal PET imaging demonstrated that [68Ga]Ga-FAP-HXN had continuous tumor uptake in FAP-positive tumors after administration compared with [68Ga]Ga-FAP-2286. In the therapeutic experiments, [177Lu]Lu-FAP-HXN showed significant antitumor activity in HEK-293-FAP xenografts at well-tolerated doses, which also exhibited longer tumor retention and better tumor growth inhibition compared with [177Lu]Lu-FAP-2286.
Conclusion
The preclinical studies revealed that radiolabeled FAP-HXN had high tumor uptake, prolonged retention, and significant anticancer efficacy in HEK-293-FAP xenografts. FAP-HXN shows promising potential as a novel theranostic radioligand for FAP-positive tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China.
- Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, China rongtiannuclear@126.com.
Zitieren
APA
Wang, R., Huang, M., Wang, W., Li, M., Wang, Y., & Tian, R. (2025). Preclinical Evaluation of 68 Ga/ 177 Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.124.268689
Vancouver
Wang R, Huang M, Wang W, Li M, Wang Y, Tian R. Preclinical Evaluation of 68 Ga/ 177 Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.124.268689
BibTeX
@article{Wang2025,
author = {Wang, Rang and Huang, Mingxing and Wang, Weichen and Li, Mufeng and Wang, Yingwei and Tian, Rong},
title = {Preclinical Evaluation of 68 Ga/ 177 Lu-Labeled FAP-Targeted Peptide for Tumor Radiopharmaceutical Imaging and Therapy},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.124.268689}
}
EUVIMED